Organ Failure: Causes, Risk Factors, and Effects

Definition / Overview

• Organ failure refers to the inability of one or more vital organs to maintain physiological homeostasis sufficient to sustain life without intervention.
• In the context of surgical transplantation, understanding organ failure is foundational - it defines the indication for transplant, dictates urgency of listing, determines operative risk, and shapes post-transplant management.
• Failure may be acute (rapid onset, potentially reversible), chronic (progressive, irreversible without transplantation), or acute-on-chronic (a decompensation superimposed on established chronic dysfunction).
• The FRACS candidate must be able to articulate the specific cause, trajectory, and systemic consequences for each organ system, and connect these to transplant candidacy criteria.

Pathophysiology and Mechanisms of Organ Failure

Final Common Pathways

Despite organ-specific differences in aetiology, organ failure converges on several common injurious mechanisms:

• Ischaemia-reperfusion injury - reduced perfusion leads to anaerobic metabolism, ATP depletion, intracellular calcium accumulation, and generation of reactive oxygen species on reperfusion; this underpins both the acute insult and progressive fibrosis.
• Inflammatory cascade activation - cytokine release (TNF-α, IL-1, IL-6) drives endothelial dysfunction, capillary leak, and remote organ injury.
• Fibrosis and architectural distortion - chronic injury stimulates stellate/myofibroblast activation, collagen deposition, and loss of functional parenchyma.
• Neurohumoral compensation - renin-angiotensin-aldosterone activation, sympathetic overdrive, and ADH release maintain short-term perfusion at the cost of progressive fluid retention, hypertension, and worsening organ injury.

Organ-Specific Pathophysiology

Renal Failure

• Loss of filtration, tubular secretion, and endocrine function (erythropoietin, activated vitamin D).
• Acute kidney injury (AKI) progresses through pre-renal, intrinsic renal, and post-renal mechanisms.
• Chronic kidney disease (CKD) results from sustained glomerular hypertension, proteinuria, tubulointerstitial fibrosis, and nephron dropout.
• End-stage renal disease (ESRD) is defined as $\text{GFR} < 15\,\text{mL/min/1.73m}^2$.

Hepatic Failure

• The liver has extensive functional reserve; failure becomes clinically apparent only when the majority of parenchyma is lost.
• Acute liver failure (ALF) involves massive hepatocyte necrosis with loss of synthetic, metabolic, and detoxification functions within weeks.
• Chronic liver failure is typically cirrhosis-mediated - portal hypertension drives varices, ascites, hepatic encephalopathy, and the hepatorenal syndrome.
• The hepatic synthetic failure results in coagulopathy ($\downarrow$ factors II, V, VII, IX, X), hypoalbuminaemia, and hypoglycaemia.

Cardiac Failure

• End-stage heart failure arises from reduced contractility (systolic dysfunction), impaired relaxation (diastolic dysfunction), or both.
• Compensatory ventricular remodelling - dilatation and hypertrophy - initially preserves output but ultimately accelerates dysfunction.
• Low cardiac output leads to reduced peripheral perfusion, neurohormonal activation, and secondary injury to kidneys, liver, and gut.

Pulmonary Failure

• Chronic respiratory failure in the transplant context typically results from obstructive disease (COPD, emphysema), suppurative disease (cystic fibrosis, bronchiectasis), or fibrotic disease (IPF).
• Gas exchange failure - hypoxaemia and/or hypercapnia - leads to pulmonary hypertension, right ventricular strain, and systemic hypoxia.

Pancreatic Failure

• Endocrine failure manifests as insulin-dependent diabetes mellitus.
• Pancreatic transplantation is reserved for patients with brittle or complicated type 1 diabetes mellitus, most often performed simultaneously with kidney transplantation (SPK).

Causes and Risk Factors

Renal Failure

• Diabetes mellitus and hypertension together account for the majority of patients reaching ESRD in Australia.
• Risk is amplified by obesity, smoking, family history of renal disease, and Indigenous Australian ethnicity.

Hepatic Failure

Cardiac Failure

• Ischaemic cardiomyopathy - most common cause in Western populations; risk factors include conventional cardiovascular risk factors.
• Dilated cardiomyopathy - idiopathic, viral myocarditis, familial, alcohol, peripartum, tachycardia-induced.
• Hypertrophic cardiomyopathy - genetic sarcomere protein mutations; risk of sudden cardiac death.
• Valvular disease - rheumatic fever, degenerative calcific disease, congenital.
• Congenital heart disease - complex lesions (e.g. hypoplastic left heart) may necessitate transplantation in paediatric patients.

Pulmonary Failure

• COPD/emphysema - smoking the dominant risk factor; $\alpha_1$-antitrypsin deficiency in younger patients.
• Idiopathic pulmonary fibrosis (IPF) - older males, smoking history, occupational dust exposure.
• Cystic fibrosis - autosomal recessive CFTR mutation; bilateral septic lung disease.
• Pulmonary arterial hypertension - idiopathic, connective tissue disease, congenital cardiac shunts.
• Bronchiectasis - recurrent infection, post-infectious, immunodeficiency.

Systemic Effects of Organ Failure

Understanding the systemic consequences of organ failure is critical for surgical candidates - these effects determine transplant urgency, complicate the perioperative course, and inform post-transplant management targets.

Effects of Renal Failure

• Hyperkalaemia ($K^+ > 5.5\,\text{mmol/L}$) requires urgent management and is a critical perioperative concern.
• Anaemia of CKD contributes significantly to fatigue and cardiovascular stress.

Effects of Hepatic Failure

• Portal hypertension - defined as hepatic venous pressure gradient $> 10\,\text{mmHg}$ - drives the major clinical complications: oesophageal varices with risk of catastrophic haemorrhage, ascites, and hypersplenism.
• The MELD score ($\text{MELD} = 3.78 \times \ln[\text{bilirubin}] + 11.2 \times \ln[\text{INR}] + 9.57 \times \ln[\text{creatinine}] + 6.43$) stratifies 90-day mortality and guides liver transplant listing priority in most jurisdictions.

Effects of Cardiac Failure

• Reduced end-organ perfusion - cardiorenal syndrome (type 2), congestive hepatopathy ("cardiac cirrhosis"), gut ischaemia.
• Pulmonary congestion - left-sided failure causes pulmonary oedema, reduced gas exchange, and dyspnoea.
• Systemic congestion - right-sided failure causes peripheral oedema, hepatomegaly, ascites, and impaired nutrition.
• Neurohormonal activation - RAAS and sympathetic overdrive accelerate disease progression.
• Functional capacity is assessed using NYHA classification (I-IV) and objectively by cardiopulmonary exercise testing (peak $\dot{V}O_2$); peak $\dot{V}O_2 < 14\,\text{mL/kg/min}$ is a threshold supporting transplant listing.

Effects of Pulmonary Failure

• Hypoxaemia and hypercapnia - impaired cognition, pulmonary hypertension, polycythaemia.
• Right ventricular failure (cor pulmonale) - a consequence of chronic pulmonary hypertension.
• Reduced exercise tolerance - progressive functional limitation, with FEV₁ (for obstructive disease) or diffusion capacity (for fibrotic disease) serving as objective markers.
• Nutritional depletion - increased work of breathing, recurrent infections, and systemic inflammation drive cachexia, particularly in cystic fibrosis.

Investigation and Monitoring of Organ Failure

General Principles

• Investigations serve three purposes: confirm the diagnosis, identify the cause, and assess severity/reversibility.
• Organ-specific severity scoring guides transplant listing and triage urgency.

Key Investigations by Organ System

Management Principles Prior to Transplantation

General

• Medical optimisation precedes transplant listing: treat reversible causes, optimise comorbidities, manage complications of organ failure.
• Multidisciplinary transplant assessment evaluates candidacy: cardiac, respiratory, nutritional, psychosocial, and immunological assessment.
• Contraindications to transplantation must be actively excluded: active malignancy, uncontrolled sepsis, severe non-correctable cardiovascular disease, non-compliance risk, active substance misuse.

Renal Failure Pre-Transplant Management

• Renal replacement therapy (haemodialysis or peritoneal dialysis) bridges patients to transplant.
• Access planning and protection of veins/vessels for future arteriovenous fistula or anastomosis.
• Anaemia management: erythropoiesis-stimulating agents, iron supplementation.
• Blood pressure control: ACE inhibitors/ARBs with monitoring for hyperkalaemia.
• Phosphate binders and activated vitamin D supplementation for metabolic bone disease.
• Pre-emptive transplantation (before dialysis initiation) confers superior outcomes where a living donor is available.

Hepatic Failure Pre-Transplant Management

• Variceal surveillance and prophylaxis (non-selective beta-blockers; endoscopic band ligation).
• Spontaneous bacterial peritonitis prophylaxis (norfloxacin or trimethoprim-sulfamethoxazole).
• Nutritional supplementation - oral/enteral support; branched-chain amino acid supplementation.
• Hepatic encephalopathy: lactulose, rifaximin, protein intake adjustment.
• Ascites: salt restriction, spironolactone, frusemide, large-volume paracentesis with albumin cover.
• Hepatorenal syndrome: terlipressin plus albumin as a bridge to transplant.
• Hepatocellular carcinoma within Milan criteria (single lesion $\leq 5\,\text{cm}$, or up to three lesions each $\leq 3\,\text{cm}$, no vascular invasion, no extrahepatic disease) is an accepted indication for liver transplant.

Complications and Special Considerations

Multi-Organ Failure

• Organ failure rarely exists in isolation at the time of transplant listing.
• Cardiorenal syndrome, hepatorenal syndrome, and portopulmonary hypertension reflect the interdependence of organ systems.
• Pre-existing renal impairment in non-renal transplant candidates often warrants consideration of combined organ transplantation (e.g. simultaneous liver-kidney, heart-kidney).
• Calcineurin inhibitor-based immunosuppression after transplant carries inherent nephrotoxicity, compounding pre-existing renal vulnerability - estimates suggest 7-21% of non-renal transplant recipients face risk of renal failure post-transplant.

Frailty and Sarcopaenia

• Progressive organ failure leads to sarcopaenia and frailty, which independently predict poor post-transplant outcomes.
• Prehabilitation programmes (nutritional optimisation, supervised exercise) aim to improve physiological reserve before transplantation.

Recurrence of Primary Disease After Transplant

• NASH, hepatitis B/C, primary sclerosing cholangitis, IgA nephropathy, FSGS, and diabetic nephropathy may all recur in the allograft.
• Strategies to minimise recurrence (antiviral therapy, metabolic syndrome management, disease-modifying agents) are integral to long-term post-transplant care.

Perioperative Management Considerations for the Transplant Surgeon

• Pre-operative optimisation of fluid and electrolyte status is mandatory - hyperkalaemia, acidosis, and volume overload must be corrected before induction of anaesthesia.
• Coagulopathy in hepatic failure requires assessment with viscoelastic testing (TEG/ROTEM) rather than relying solely on conventional INR; targeted correction with cryoprecipitate, platelets, and fibrinogen concentrate guided by point-of-care testing.
• Timing of transplant in acute liver failure (ALF) is time-critical - King's College Criteria identify patients unlikely to survive without transplantation (paracetamol: arterial pH $< 7.30$, or creatinine $> 300\,\mu\text{mol/L}$ + INR $> 6.5$ + grade III/IV encephalopathy; non-paracetamol: INR $> 6.5$ alone, or any three of five defined variables).
• Intraoperative haemodynamic instability in end-stage liver failure is anticipated: hyperdynamic pre-reperfusion state; reperfusion syndrome (hypotension, arrhythmia, coagulopathy) on graft unclamping.
• Post-transplant, immediate assessment of graft function is paramount - primary non-function requires urgent re-listing and retransplantation.
• Long-term surveillance for infection, malignancy (particularly post-transplant lymphoproliferative disorder and skin cancers), metabolic complications of immunosuppression, and calcineurin inhibitor nephrotoxicity forms the backbone of post-transplant follow-up.